NCT02987114View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions

Epilepsy Intractable

Interventions

DRUG

PLT101

PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food

Trial Locations (1)

Unknown

Pediatric Epilepsy department- Souraskey Medical center, Tel Aviv